Inspire Medical Systems, Inc.

Overview

1. "How the company got here" Inspire Medical Systems was founded in 2007, emerging from technology originally developed by Medtronic, a large medical device company. The company's journey began with a focus on developing a new way to treat obstructive sleep apnea (OSA), a condition where breathing repeatedly stops and starts during sleep. A significant turning point came in 2014 when Inspire therapy received approval from the U.S. Food and Drug Administration (FDA), marking a major step towards making the treatment available to patients. The company went public in 2018, which provided capital to further develop and commercialize its innovative therapy. More recently, in 2023, the FDA expanded the approved patient population for Inspire therapy, allowing more individuals to be eligible for treatment. 2. "What it actually does" Inspire Medical Systems develops and sells an implantable medical device designed to treat moderate to severe obstructive sleep apnea (OSA). The Inspire system is a neurostimulation technology that works inside the body to keep a patient's airway open during sleep. Unlike other common sleep apnea treatments like Continuous Positive Airway Pressure (CPAP) machines, which involve wearing a mask and hose, Inspire therapy is a mask-free solution. The system consists of an implanted device that monitors breathing and stimulates a nerve to move the tongue forward, preventing airway obstruction. Patients control the therapy with a small remote and can track their progress with a mobile app. 3. "Inspire Therapy" Inspire Medical Systems operates with a single, primary business line centered around its innovative Inspire therapy for obstructive sleep apnea (OSA). This therapy is the company's core product and the overwhelming driver of its revenue. The Inspire system includes the implantable components, such as the neurostimulator and leads that sense breathing and stimulate the airway, as well as a patient remote and software for managing and adjusting the therapy. The company sells this system to hospitals and outpatient surgery centers. While the U.S. is its primary market, Inspire also has a growing presence in select European countries and Japan. 4. "What management is betting on now" Inspire Medical Systems' current strategy focuses on expanding access and adoption of its Inspire therapy. Management is investing in initiatives to increase patient awareness through direct-to-consumer marketing and to broaden the network of referring physicians, encouraging more doctors to recommend the therapy. They are also working to expand the capacity and productivity of centers that perform the implant surgery and to improve the process for insurance coverage and payment (reimbursement). Additionally, the company is focused on advancing its international expansion efforts and continuing to invest in product development and clinical research to gather more evidence supporting the therapy's effectiveness. A recent strategic growth plan, called "Project Horizon," aims to create additional capacity for investment in these growth initiatives by streamlining operations and optimizing the supply chain.